Exelixis is laying off 130 workers, roughly 11% of its workforce, and closing its Pennsylvania office. The company hired heavily during and after the pandemic and is reorganizing to concentrate operations in Alameda, California. The reorganization aims to align long-term business needs and operate as a single, cohesive team from Alameda, with expectations of reopening positions as new roles at headquarters. A WARN notice reports 71 layoffs in California and 33 more outside the state who report to California managers, with roles ending in late October and November. The cuts include vice presidents, senior staff, scientists, and clinical trials managers. The layoffs occur despite the success of the cabozantinib drug franchise.
It said the move is meant to "reorganize the company's structure to focus largely on our operations in Alameda, California." "The reorganization was based on an evaluation of our long-term business needs to set Exelixis up for success now and in the future," the statement said. It described Exelixis' plan to work as a "single, cohesive team" from Alameda as the best way to help patients and said the company expects to reopen positions as new roles at the headquarters.
Exelixis, a high-flying biotech company that creates anti-cancer drugs in Alameda, is laying off 130 workers. The company's cuts were first reported by Fierce Biotech, and the number was confirmed to SFGATE by external spokesperson Hal Mackins on Thursday. The layoff round amounts to about 11% of the staff Exelixis began the year withand, per the company's statement that Mackins sent, includes the shutdown of the company's Pennsylvania office.
Collection
[
|
...
]